Dermorphin, a short amino-acid chain from frog skin that acts on the same receptors as morphine, was tested for pain relief and is sold by unregulated vendors. One small, unrepeated surgical trial found an injection into the spinal fluid relieved pain longer than morphine; nothing measured relates to ageing or lifespan. Opioid harms apply: slowed breathing, dependence, hormone suppression; the frog-secretion ritual has caused deaths, mostly not through this peptide. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Serum sodium | 135–145 mmol/L | Safety check; a result below range stops use |
| Breathing during sleep (overnight oximetry or sleep study) | 30 or more breathing pauses per hour marks the group at greatest risk | Unwitnessed apnoea is the mechanism of opioid death |
| Total testosterone (men) | 264–916 ng/dL | Sustained mu-opioid activity suppresses it |
| Luteinizing hormone | 1.7–8.6 IU/L in men, cycle-dependent in women | Separates central from testicular suppression |
| Prolactin | 4–15 ng/mL in men, 4–23 ng/mL in women | Persistent rise signals continuing pituitary effect |
| Morning cortisol | 5–25 µg/dL at 8 a.m. | Safety check; a low value indicates a blunted stress response |
| Thyroid-stimulating hormone | 0.4–4.0 mIU/L | Dermorphin raised it in volunteers |
| Free thyroxine | Not specified in the ER | Paired with thyroid-stimulating hormone if out of range |
Cadence: Sodium, breathing during sleep and baseline hormones before any exposure. No established cadence for this compound; in class practice, hormones are rechecked after roughly 4 to 8 weeks of repeated exposure and then every 6 to 12 months, and sodium before each ritual-route exposure and whenever vomiting and heavy water intake occur together.